このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

双極性障害(BD)におけるケトジェニックダイエットの治療効果の根底にある神経生物学的メカニズムの研究

2026年11月9日 更新者:Mary Phillips, MD MD (Cantab)、University of Pittsburgh

双極性障害(BD)におけるケトジェニックダイエットの治療効果の根底にある神経生物学的メカニズムの解明:学際的なメカニズム研究

The investigators aim to examine the effect of the ketogenic diet on brain activity, metabolism, and emotions in adults with Bipolar Disorder (BD).

調査の概要

詳細な説明

The investigators hypothesize that a ketogenic diet will enhance levels of the ketone body β-Hydroxybutyrate (beta OHB), resulting in reduced mania/hypomania severity and predisposition to mania/hypomania in individuals with BD. To test this hypothesis in depth, the investigators will use a novel, multidisciplinary mechanistic study using multimodal neuroimaging, peripheral markers of mitochondrial metabolism, and participant-derived induced pluripotent stem cell (iPSC)-derived organoids.

研究の種類

介入

入学 (推定)

107

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Pennsylvania
      • Pittsburgh、Pennsylvania、アメリカ、15213
        • 募集
        • University of Pittsburgh Medical Center
        • コンタクト:
        • 主任研究者:
          • Mary L Phillps, MD, MD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~40年 (大人)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion Criteria:

All participants:

  • 18-40 years of age
  • Not following a ketogenic diet

BD hypomanic group (n=30):

  • Meeting sex proportion: 50% female
  • Meeting diagnosis proportion: 50:50% Bipolar I: Bipolar II (BDI:II) (Diagnostic and Statistical Manual of Mental Disorders 5; DSM-5)
  • Score greater than 10 on the Young Mania Rating Scale score(YMRS)
  • BD medications will be allowed as in our previous studies: any combination of atypical antipsychotics, lithium, antidepressants, anxiolytics (common in BD)
  • Has a primary care provider (if enrolled in ketogenic diet phase)

BD euthymic group (n=30):

  • Meeting sex proportion: 50% female
  • Meeting diagnosis proportion: 50:50% BDI:II (DSM-5)
  • Score less than or equal to 10 on YMRS
  • BD medications will be allowed as in our previous studies: any combination of atypical antipsychotics, lithium, antidepressants, anxiolytics (common in BD)
  • Has a primary care provider (if enrolled in ketogenic diet phase)

Healthy Control (HC) Group (n=30):

  • Sex matched with BD groups
  • No psychiatric history

Exclusion Criteria:

All participants:

  • Not between 18-40 years of age
  • History of head injury, neurological, pervasive developmental disorder (e.g. autism), systemic medical disease and treatment (medical records, participant report)
  • Mini-Mental State Examination score (cognitive state) <24
  • Premorbid National Adult Reading Test Intelligent Quotient (NAART IQ) estimate<85
  • Visual disturbance: <20/40 Snellen visual acuity
  • History of alcohol/substance use disorder (SUD; all substances, including nicotine), and/or illicit substance use (except cannabis) over the last 6 months (SCID-5). Note: lifetime/present cannabis use (at non-abuse (<3 times in the past month) and non SUD levels) will be allowed, given its common usage in BD and young adults. Cannabis SUD over the last 6 months will not be allowed. Urine tests on scan days will exclude current illicit substance use (except cannabis). Salivary alcohol tests on scan days will exclude intoxicated individuals
  • MRI exclusion: metallic objects, e.g., surgical implants; claustrophobia; positive pregnancy test for females or self-report pregnancy
  • Unable to understand English
  • Conditions related to the pancreas, liver, thyroid or gallbladder.
  • Taking anticoagulants and/or those with blood dyscrasias (illnesses) who have coagulation disorders (eg, hemophilia) because of the ketomojo finger stick blood tests
  • Scoring 3 or higher on positive symptom factor questions on the Positive and Negative Syndrome Scale (PANSS) questionnaire (indicative of psychotic symptoms)
  • Currently following a ketogenic diet
  • Head circumference larger than 24 inches (62cm) and/or chest circumference larger than 55 inches (139 cm)
  • Taken medications for diabetes and weight loss (e.g., Wegovy, Orlistat) in the past month

BD hypomanic group:

  • Must be meeting sex proportions: not 50% female
  • Must be meeting diagnosis proportions: not 50:50% BDI:II (DSM-5)
  • Diagnosis of BD in a manic or euthymic episode
  • Score 10 or lower on the Young Mania Rating Scale score(YMRS)
  • Using psychotropic medications other than those allowed in inclusion criteria
  • Does not have a smartphone with a) iOS version 12.0 or above, or b) Android version 8 and later to use with the Keto-Mojo app
  • Does not have a primary care provider (if enrolled in ketogenic diet phase)

BD euthymic group:

  • Not meeting sex proportion: not 50% female
  • Not meeting diagnosis proportion: not 50:50% BDI:II
  • Diagnosis of BD in a depressive, hypomanic, or manic episode
  • Score greater than 10 on YMRS
  • Using psychotropic medications other than those allowed in inclusion criteria
  • Does not have a smartphone with a) iOS version 12.0 or above, or b) Android version 8 and later to use with the Keto-Mojo app
  • Does not have a primary care provider (if enrolled in ketogenic diet phase)

Healthy Control (HC) Group

  • Not sex-matched with BD groups
  • Has psychiatric history

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:基礎科学
  • 割り当て:ランダム化
  • 介入モデル:クロスオーバー割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:1st phase Non-ketogenic Diet / 2nd phase Ketogenic Diet

Participants with Bipolar Disorder will consume a non-ketogenic diet for the first phase of the study and then a ketogenic diet for the second phase of the study

Consuming a non-ketogenic diet

Consuming a ketogenic diet

実験的:1st phase Ketogenic Diet / 2nd phase Non-ketogenic Diet

Participants with Bipolar Disorder will consume a ketogenic diet for the first phase of the study and then a non-ketogenic diet for the second phase of the study

Consuming a non-ketogenic diet

Consuming a ketogenic diet

他の:No diet

Participants without Bipolar Disorder will not participate in the diet phases of the study

Participants without Bipolar Disorder will not participate in the diet phases of the study

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Blood oxygen level-dependent (BOLD) signal at Scan 1
時間枠:Baseline Scan 1 (all participants)

The blood oxygen level-dependent (BOLD) signal indicates brain activity and connectivity

Baseline Scan 1 (all participants)
Blood oxygen level-dependent (BOLD) signal at Scan 2
時間枠:End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

The blood oxygen level-dependent (BOLD) signal indicates brain activity and connectivity

End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Blood oxygen level-dependent (BOLD) signal at Scan 3
時間枠:End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

The blood oxygen level-dependent (BOLD) signal indicates brain activity and connectivity

End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Manic symptoms at Scan 1
時間枠:Baseline Scan 1 (all participants)

The Young Mania Rating Scale (YMRS) indicates the level of manic symptoms with a total score that varies between zero (better outcome) and 60 (worse outcome)

Baseline Scan 1 (all participants)
Manic symptoms at Scan 2
時間枠:Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

The Young Mania Rating Scale (YMRS) indicates the level of manic symptoms with a total score that varies between zero (better outcome) and 60 (worse outcome)

Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Manic symptoms at Scan 3
時間枠:Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

The Young Mania Rating Scale (YMRS) indicates the level of manic symptoms with a total score that varies between zero (better outcome) and 60 (worse outcome)

Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting Glucose at Baseline
時間枠:Baseline (all participants)

Fasting glucose blood levels

Baseline (all participants)
Fasting lipids at Baseline
時間枠:Baseline (all participants)

Fasting lipid blood levels

Baseline (all participants)
Fasting hepatic function panel at Baseline: total protein
時間枠:Baseline (all participants)

Fasting levels of total protein in the blood

Baseline (all participants)
Fasting hepatic function panel at Baseline: albumin
時間枠:Baseline (all participants)

Fasting levels of albumin in the blood

Baseline (all participants)
Fasting hepatic function panel at Baseline: bilirubin
時間枠:Baseline (all participants)

Fasting levels of bilirubin in the blood

Baseline (all participants)
Fasting hepatic function panel at Baseline: liver enzyme
時間枠:Baseline (all participants)

Fasting levels of liver enzyme in the blood

Baseline (all participants)
Fasting Glucose at halfway point through first dietary phase
時間枠:Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)

Fasting glucose blood levels

Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting lipids at halfway point through first dietary phase
時間枠:Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)

Fasting lipid blood levels

Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at halfway point through first dietary phase: total protein
時間枠:Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)

Fasting levels of total protein in the blood

Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at halfway point through first dietary phase: albumin
時間枠:Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)

Fasting levels of albumin in the blood

Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at halfway point through first dietary phase: bilirubin
時間枠:Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)

Fasting levels of bilirubin in the blood

Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at halfway point through first dietary phase: liver enzyme
時間枠:Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)

Fasting levels of liver enzyme in the blood

Halfway point through first dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting Glucose at end of first dietary phase
時間枠:End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Fasting glucose blood levels

End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting lipids at end of first dietary phase
時間枠:End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Fasting lipid blood levels

End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at end of first dietary phase: total protein
時間枠:End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Fasting levels of total protein in the blood

End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at end of first dietary phase: albumin
時間枠:End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Fasting levels of albumin in the blood

End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at end of first dietary phase: bilirubin
時間枠:End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Fasting levels of bilirubin in the blood

End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at end of first dietary phase: liver enzyme
時間枠:End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Fasting levels of liver enzyme in the blood

End of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting Glucose at halfway point through second dietary phase
時間枠:Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)

Fasting glucose blood levels

Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting lipids at halfway point through second dietary phase
時間枠:Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)

Fasting lipid blood levels

Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at halfway point through second dietary phase: total protein
時間枠:Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)

Fasting levels of total protein in the blood

Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at halfway point through second dietary phase: albumin
時間枠:Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)

Fasting levels of albumin in the blood

Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at halfway point through second dietary phase: bilirubin
時間枠:Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)

Fasting levels of bilirubin in the blood

Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at halfway point through second dietary phase: liver enzyme
時間枠:Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)

Fasting levels of liver enzyme in the blood

Halfway point through second dietary phase (4-5 weeks) (participants with Bipolar Disorder)
Fasting Glucose at end of second dietary phase
時間枠:End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Fasting glucose blood levels

End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting lipids at end of second dietary phase
時間枠:End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Fasting lipids blood levels

End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at end of second dietary phase: total protein
時間枠:End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Fasting levels of total protein in the blood

End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at end of second dietary phase: albumin
時間枠:End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Fasting levels of albumin in the blood

End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at end of second dietary phase: bilirubin
時間枠:End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Fasting levels of bilirubin in the blood

End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Fasting hepatic function at end of second dietary phase: liver enzyme
時間枠:End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Fasting levels of liver enzyme in the blood

End of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Gamma-aminobutyric acid (GABA) at Baseline
時間枠:Baseline Scan 1 (all participants)

Gamma-aminobutyric acid (GABA) concentrations in the brain

Baseline Scan 1 (all participants)
Glutamate at Baseline
時間枠:Baseline Scan 1 (all participants)

Glutamate concentrations in the brain

Baseline Scan 1 (all participants)
Lactate at Baseline
時間枠:Baseline Scan 1 (all participants)

Lactate concentrations in the brain

Baseline Scan 1 (all participants)
Gamma-aminobutyric acid (GABA) at end of first dietary phase
時間枠:Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Gamma-aminobutyric acid (GABA) concentrations in the brain

Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Glutamate at end of first dietary phase
時間枠:Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Glutamate concentrations in the brain

Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Lactate at end of first dietary phase
時間枠:Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Lactate concentrations in the brain

Scan 2 at end of first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Gamma-aminobutyric acid (GABA) at end of second dietary phase
時間枠:Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Gamma-aminobutyric acid (GABA) concentrations in the brain

Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Glutamate at end of second dietary phase
時間枠:Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Glutamate concentrations in the brain

Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Lactate at end of second dietary phase
時間枠:Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Lactate concentrations in the brain

Scan 3 at end of second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

二次結果の測定

結果測定
メジャーの説明
時間枠
Average total sleep time during Ketogenic vs Normal diet
時間枠:Wrist actigraphy will be collected throughout the 8-10wk ketogenic diet and normal diet study intervals

Total sleep time will be assessed using wrist actigraphy. Wrist actigraphy will be collected continuously, at-home.

Wrist actigraphy will be collected throughout the 8-10wk ketogenic diet and normal diet study intervals
Average rest-activity rhythm interdaily stability during Ketogenic vs Normal diet
時間枠:Wrist actigraphy will be collected throughout the 8-10 wk ketogenic diet and normal diet study intervals.

Rest-activity rhythm interdaily stability will be assessed using wrist actigraphy. Wrist actigraphy will be collected continuously, at-home

Wrist actigraphy will be collected throughout the 8-10 wk ketogenic diet and normal diet study intervals.
Ecological momentary assessments (EMA) during the first dietary phase: Mood monitoring
時間枠:The first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Mood monitoring in real time in participants with Bipolar Disorder: rate mood on a scale of 1-7 with 1 being very low mood and 7 being very high mood

The first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Ecological momentary assessments (EMA) during the first dietary phase: Energy monitoring
時間枠:The first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Energy monitoring in real time in participants with Bipolar Disorder: rate energy on a scale of 1-7 with 1 being very low energy and 7 being very high energy

The first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Ecological momentary assessments (EMA) during the first dietary phase: Suicidality monitoring
時間枠:The first dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Suicidality monitoring in real time in participants with Bipolar Disorder: answer yes or no to having self-harm/suicide thoughts and plans

The first dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Ecological momentary assessments (EMA) during the second dietary phase: Mood monitoring
時間枠:The second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Mood monitoring in real time in participants with Bipolar Disorder: rate mood on a scale of 1-7 with 1 being very low mood and 7 being very high mood

The second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Ecological momentary assessments (EMA) during the second dietary phase: Energy monitoring
時間枠:The second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Energy monitoring in real time in participants with Bipolar Disorder: rate energy on a scale of 1-7 with 1 being very low energy and 7 being very high energy

The second dietary phase (8-10 weeks) (participants with Bipolar Disorder)
Ecological momentary assessments (EMA) during the second dietary phase: Suicidality monitoring
時間枠:The second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

Suicidality monitoring in real time in participants with Bipolar Disorder: answer yes or no to having self-harm/suicide thoughts and plans

The second dietary phase (8-10 weeks) (participants with Bipolar Disorder)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Mary Phillips, MD、University of Pittsburgh

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年1月12日

一次修了 (推定)

2027年6月1日

研究の完了 (推定)

2027年6月1日

試験登録日

最初に提出

2023年9月22日

QC基準を満たした最初の提出物

2023年10月5日

最初の投稿 (実際)

2023年10月13日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月12日

QC基準を満たした最後の更新が送信されました

2026年11月9日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Informed consent will be collected from study participants that allows for broad sharing of participants' de-identified data. Data transfer procedures will be in accordance with all Institutional Review Board guidelines and federal regulations including HIPAA (Health Insurance Portability and Accountability Act of 1996).

IPD 共有時間枠

The principal investigators (PIs) reserve the right to publish on the stated aims in a timely manner. Data will be available for addressing other research questions (i.e. which are not described in funded/pending grants) as soon as the data have been checked for accuracy (a period which will be no later than one year after the completion of each assessment). After the study has ended, the study investigators will continue to test the stated aims, but will also continue to solicit collaborations with outside researchers and to consider data requests in a timely manner.

IPD 共有アクセス基準

Outside investigators must submit a 1)proposal of the study aims, hypotheses, variables/constructs, analytic approach, and estimated duration of the proposed research; 2)resume, qualifications, source of financial support, and conflict of interest statement; 3)sign a data-sharing agreement and confidentiality statement that stipulates using the data for the stated research purposes only, securing the data using appropriate computer technology, not manipulating the data in order to identify participants, acknowledging the grant that supported data collection and management in publications/presentations, and destroying or returning the data after analyses are complete; 4)obtain approval from their Institutional Review Board, and along with other staff members who have access to the data, submit certificates of the University of Pittsburgh Education and Certification Program in Research Practice Fundamentals or provide written documentation of similar human subjects protection training.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する